Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorMoore, Kate M.
dc.contributor.authorCerqueira, Vera
dc.contributor.authorMacLeod, Kenneth G.
dc.contributor.authorMullen, Peter
dc.contributor.authorHayward, Richard L.
dc.contributor.authorGreen, Simon
dc.contributor.authorHarrison, David James
dc.contributor.authorCameron, David A.
dc.contributor.authorLangdon, Simon P.
dc.date.accessioned2022-03-10T11:30:15Z
dc.date.available2022-03-10T11:30:15Z
dc.date.issued2022-02-28
dc.identifier.citationMoore , K M , Cerqueira , V , MacLeod , K G , Mullen , P , Hayward , R L , Green , S , Harrison , D J , Cameron , D A & Langdon , S P 2022 , ' Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα and cell-cycle signaling in a breast cancer model ' , Exploration of Targeted Anti-tumor Therapy , vol. 3 , pp. 97-116 . https://doi.org/10.37349/etat.2022.00074en
dc.identifier.issn2692-3114
dc.identifier.otherPURE: 277588572
dc.identifier.otherPURE UUID: 439724fa-c806-485e-b95d-c2c02cea0254
dc.identifier.otherORCID: /0000-0001-9041-9988/work/109766648
dc.identifier.urihttps://hdl.handle.net/10023/25022
dc.descriptionThese studies were supported by grants from Cancer Research UK (C503/A5010 and C1938/A6769).en
dc.description.abstractAim : A model of progressively endocrine-resistant breast cancer was investigated to identify changes that can occur in signaling pathways after endocrine manipulation. Methods : The MCF7 breast cancer model is sensitive to estrogens and anti-estrogens while variant lines previously derived from wild-type MCF7 are either relatively 17β-estradiol (E2)-insensitive (LCC1) or fully resistant to estrogen and anti-estrogens (LCC9). Results : In LCC1 and LCC9 cell lines, loss of estrogen sensitivity was accompanied by loss of growth response to transforming growth factor alpha (TGFα), heregulin-beta and pertuzumab. LCC1 and LCC9 cells had enhanced AKT phosphorylation relative to MCF7 which was reflected in downstream activation of phospho-mechanistic target of rapamycin (mTOR), phospho-S6, and phospho-estrogen receptor alpha Ser167 [ERα(Ser167)]. Both AKT2 and AKT3 were phosphorylated in the resistant cell lines, but siRNA knockdown suggested that all three AKT isoforms contributed to growth response. ERα(Ser118) phosphorylation was increased by E2 and TGFα in MCF7, by E2 only in LCC1, but by neither in LCC9 cells. Multiple alterations in E2-mediated cell cycle control were identified in the endocrine-resistant cell lines including increased expression of MYC, cyclin A1, cyclin D1, cyclin-dependent kinase 1 (CDK1), CDK2, and hyperphosphorylated retinoblastoma protein (ppRb), whereas p21 and p27 were reduced. Estrogen modulated expression of these regulators in MCF7 and LCC1 cells but not in LCC9 cells. Seliciclib inhibited CDK2 activation in MCF7 cells but not in resistant variants; in all lines, it reduced ppRb, increased p53 associated responses including p21, p53 up-regulated modulator of apoptosis (PUMA), and p53 apoptosis-inducing protein 1 (p53AIP1), inhibited growth, and produced G2/M block and apoptosis. Conclusions : Multiple changes occur with progression of endocrine resistance in this model with AKT activation contributing to E2 insensitivity and loss of ERα(Ser118) phosphorylation being associated with full resistance. Cell cycle regulation is modified in endocrine-resistant breast cancer cells, and seliciclib is effective in both endocrine-sensitive and resistant diseases.
dc.format.extent20
dc.language.isoeng
dc.relation.ispartofExploration of Targeted Anti-tumor Therapyen
dc.rightsCopyright © The Author(s) 2022. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.en
dc.subjectBreast canceren
dc.subjectEndocrine resistanceen
dc.subjectEstrogenen
dc.subjecterbB receptoren
dc.subjectSelicicliben
dc.subjectQH301 Biologyen
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectNDASen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccQH301en
dc.subject.lccRC0254en
dc.subject.lccRMen
dc.titleCollateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα and cell-cycle signaling in a breast cancer modelen
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. Sir James Mackenzie Institute for Early Diagnosisen
dc.contributor.institutionUniversity of St Andrews. Cellular Medicine Divisionen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.identifier.doihttps://doi.org/10.37349/etat.2022.00074
dc.description.statusPeer revieweden
dc.date.embargoedUntil2022-02-28
dc.identifier.urlhttps://www.explorationpub.com/Journals/etat/Special_Issues/48en


This item appears in the following Collection(s)

Show simple item record